Achieving target voriconazole concentrations more accurately in children and adolescents

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3090-3097

  Neely, Michael ^a   Margol, Ashley ^a   Fu, Xiaowei ^a   Van Guilder, Michael ^a   Bayard, David ^a   Schumitzky, Alan ^a   Orbach, Regina ^a   Liu, Siyu ^b   Louie, Stan ^b   Hope, William ^c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; BAYES THEOREM; CHILD; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MICHAELIS CONSTANT; MINIMUM PLASMA CONCENTRATION; NONPARAMETRIC POPULATION MODEL; PHARMACOKINETICS; PRIORITY JOURNAL; STATISTICAL MODEL; STEADY STATE; CLINICAL TRIAL; DRUG MONITORING; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ALGORITHMS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; VORICONAZOLE; YOUNG ADULT;

EID: 84929643042     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00032-15     Document Type: Article

References (34)

1. Dolton MJ, Ray JE, Chen SC-A, Ng K, Pont LG, McLachlan AJ. 2012. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 56:4793-4799. http://dx.doi.org/10.1128/AAC.00626-12.
2. Troke PF, Hockey HP, Hope WW. 2011. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 55:4782-4788. http://dx.doi.org/10.1128/AAC.01083-10.
3. Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, Kurokawa M. 2009. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 89:592-599. http://dx.doi.org/10.1007/s12185-009-0296-3.
4. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201-211. http://dx.doi.org/10.1086/524669.
5. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. 2006. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50:1570-1572. http://dx.doi.org/10.1128/AAC.50.4.1570-1572.2006.
6. Mitsani D, Nguyen MH, Shields RK, Toyoda Y, Kwak EJ, Silveira FP, Pilewski JM, Crespo MM, Bermudez C, Bhama JK, Clancy CJ. 2012. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 56:2371-2377. http://dx.doi.org/10.1128/AAC.05219-11.
7. Miyakis S, van Hal SJ, Ray J, Marriott D. 2010. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 16:927-933. http://dx.doi.org/10.1111/j.1469-0691.2009.02990.x.
8. Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, Song KH, Choe PG, Kim NJ, Jang IJ, Oh MD, Yu KS. 2012. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 55:1080-1087. http://dx.doi.org/10.1093/cid/cis599.
9. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. 2010. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 50:27-36. http://dx.doi.org/10.1086/648679.
10. Soler-Palacín P, Frick MA, Martín-Nalda A, Lanaspa M, Pou L, Roselló E, de Heredia CD, Figueras C. 2012. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother 67:700-706. http://dx.doi.org/10.1093/jac/dkr517.
11. Choi S-H, Lee S-Y, Hwang J-Y, Lee SH, Yoo KH, Sung KW, Koo HH, Kim Y-J. 2013. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer 60:82-87. http://dx.doi.org/10.1002/pbc.24262.
12. Siopi M, Mavridou E, Mouton JW, Verweij PE, Zerva L, Meletiadis J. 2014. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. J Antimicrob Chemother 69: 1611-1619. http://dx.doi.org/10.1093/jac/dku023.
13. Al-Saigh R, Elefanti A, Velegraki A, Zerva L, Meletiadis J. 2012. In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model. Antimicrob Agents Chemother 56:5321-5327. http://dx.doi.org/10.1128/AAC.00549-12.
14. Andes D, Marchillo K, Stamstad T, Conklin R. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47:3165-3169. http://dx.doi.org/10.1128/AAC.47.10.3165-3169.2003.
15. Drusano GL. 2010. How many steps along the path is too far? Clin Infect Dis 50:37-39. http://dx.doi.org/10.1086/648680.
16. Neely MN, Fu X, Lu S, Margol A, Louie SG, Hope WW. 2014. Voriconazole pharmacokinetics and metabolism to voriconazole-N-oxide in children is age independent with more aggressive dosing, abstr A-723. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
17. Bruggemann RJM, Donnelly JP, Aarnoutse RE, Warris A, Blijlevens NMA, Mouton JW, Verweij PE, Burger DM. 2008. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 30:403-411. http://dx.doi.org/10.1097/FTD.0b013e31817b1a95.
18. Decosterd LA, Rochat B, Pesse B, Mercier T, Tissot F, Widmer N, Bille J, Calandra T, Zanolari B, Marchetti O. 2010. Multiplex ultraperformance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob Agents Chemother 54:5303-5315. http://dx.doi.org/10.1128/AAC.00404-10.
19. Alffenaar JWC, Wessels AMA, van Hateren K, Greijdanus B, Kosterink JGW, Uges DRA. 2010. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 878:39-44. http://dx.doi.org/10.1016/j.jchromb.2009.11.017.
20. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34:467-476. http://dx.doi.org/10.1097/FTD.0b013e31825c4ba6.
21. Karlsson MO, Lutsar I, Milligan PA. 2009. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 53:935-944. http://dx.doi.org/10.1128/AAC.00751-08.
22. Hope WW. 2012. Population pharmacokinetics of voriconazole in adults. Antimicrob Agents Chemother 56:526-531. http://dx.doi.org/10.1128/AAC.00702-11.
23. Åsberg A, Midtvedt K, van Guilder M, Størset E, Bremer S, Bergan S, Jelliffe R, Hartmann A, Neely MN. 2013. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transpl Int 26:1198-1207. http://dx.doi.org/10.1111/tri.12194.
24. Burnham KP, Anderson DR. 2010. Model selection and multi-model inference. Springer Scienceo+Business Media, New York, NY.
25. Comets E, Brendel K, Mentré F. 2008. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90:154-166. http://dx.doi.org/10.1016/j.cmpb.2007.12.002.
26. Bayard DS, Milman MH, Schumitzky A. 1994. Design of dosage regimens: a multiple model stochastic control approach. Int J Biomed Comput 36:103-115. http://dx.doi.org/10.1016/0020-7101(94)90100-7.
27. Jelliffe R, Bayard D, Milman M, Van Guilder M, Schumitzky A. 2000. Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens. Ther Drug Monit 22:346-353. http://dx.doi.org/10.1097/00007691-200006000-00018.
28. Neely M, Jelliffe R. 2008. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol 48:1081-1091. http://dx.doi.org/10.1177/0091270008321789.
29. Hope WW, Vanguilder M, Donnelly JP, Blijlevens NMA, Bruggemann RJM, Jelliffe RW, Neely MN. 2013. Software for dosage individualization of voriconazole for immunocompromised patients. Antimicrob Agents Chemother 57:1888-1894. http://dx.doi.org/10.1128/AAC.02025-12.
30. Bayard DS, Jelliffe RW, Neely MN. 2013. Bayes risk as an alternative to Fisher information in determining experimental designs for nonparametric models. Presented at Population Optimal Design of Experiments Workshop, Windlesham, Surrey, United Kingdom. http://www.maths.qmul.ac.uk/bb/PODE/PODE2013-Slides/PODE2013-RogerJelliffe.pdf.
31. Neely MN, Bayard DS, Hope WW. 2013. Multiple model optimal (MMopt) sampling for first dose oral voriconazole TDM in children. Abstr Int Assoc Ther Drug Monit Clin Toxicol Annu Meet, Salt Lake City, UT. International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Rochester, NY.
32. Friberg LE, Ravva P, Karlsson MO, Liu P. 2012. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother 56:3032-3042. http://dx.doi.org/10.1128/AAC.05761-11.
33. Owusu Obeng A, Egelund EF, Alsultan A, Peloquin CA, Johnson JA. 2014. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy 34:703-718. http://dx.doi.org/10.1002/phar.1400.
34. Narita A, Muramatsu H, Sakaguchi H, Doisaki S, Tanaka M, Hama A, Shimada A, Takahashi Y, Yoshida N, Matsumoto K, Kato K, Kudo K, Furukawa-Hibi Y, Yamada K, Kojima S. 2013. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children. J Pediatr Hematol Oncol 35:e219-e223. http://dx.doi.org/10.1097/MPH.0b013e3182880eaa.